Page 4 - Peter Guenter News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced changes in its operating model for the Healthcare business sector. Chris Round will become President of EMD Serono leading the North America Healthcare business; Andrew Paterson will assume the position of Chief Marketing Officer; and recruitment is ongoing for the position of Head of China & International. “Our redesigned Healthcare organization creates dedicated leadership for our strategic priorities with a focus on growth,” said Peter Guenter, Member of the Executive Board of Merck KGaA, Darmstad...

May 18, 2021 11:39am Germany-based Merck KGaA saw an 8.6% increase in sales in 2020 and looks for even more success with reorganization of its healthcare unit in North America as it tries to spur sales of Mavenclad, Bavencio and Tepmetko. (Fierce Pharma) Belen Garijo took over last month as CEO at Merck KGaA and she’s not wasting time putting her imprint on the company. On Tuesday, the Germany-based company said it had tapped Chris Round as president at its North America healthcare unit, replacing Andrew Patterson, who'll step into the brand-new role of chief marketing officer. By beefing u...

MERCK KGAA (MKKGY) Q1 2021 Earnings Call Transcript Motley Fool Transcribers © The Motley Fool Logo of jester cap with thought bubble. MERCK KGAA (OTC: MKKGY) Operator Good day, and welcome to the Merck Quarter One 2021 Analysts Telco Conference Call. [Operator Instructions] At this time, I would like to turn the conference over to Constantin Fest. Please go ahead.SPONSORED: 10 stocks we like better than Merck KGaA When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Foo...

Debiopharm Grants a Worldwide Exclusive License to Merck KGaA, Darmstadt, Germany for the Development and Commercialization of Xevinapant USA - English Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated locally advanced squamous cell carcinoma of the head and neck, in combination with current standard of care A Phase II trial reported that xevinapant plus chemoradiotherapy reduced risk of death by 51% vs standard of care in this patient population; Phase III TrilynX study initiated in September 2020 Merck KGaA,...

Debiopharm Grants a Worldwide Exclusive License to Merck for the Development and Commercialization of Xevinapant - Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated locally advanced squamous cell carcinoma of the head and neck, in combination with current standard of care - A Phase II trial reported that xevinapant plus chemoradiotherapy reduced risk of death by 51% vs standard of care in this patient population; Phase III TrilynX study initiated in September 2020 - Merck gains exclusive global development ...